On Thursday, Shares of Staples, Inc. (NASDAQ:SPLS), gained 0.73% to $16.46.
Staples, declared Microsoft Match, a new program from Staples that assists customers determine the best Windows device for their needs. Microsoft Match is accessible exclusively on www.staples.com/microsoftmatch and in select Staples stores.
Microsoft Match lets customers answer a few simple questions aimed at finding the benefits and features most important to them. The Match program finds the most suitable Windows PC, tablet or laptop.
Microsoft Match assists customers find their perfect Windows device and gives customers access to inventory across stores and Staples warehouses. It also allows customers to receive delivery wherever and whenever they choose. With Staples’ Price Match Guarantee and Staples Rewards, customers will pay the lowest price and earn up to 5% back in Rewards on any purchase.
Staples, Inc., together with its subsidiaries, operates office products superstores. It operates through three segments: North American Stores & Online, North American Commercial, and International Operations.
Shares of Melco Crown Entertainment Limited (NASDAQ:MPEL), gained 1.39% to $20.02, during its last trading session.
Melco Crown Entertainment, stated its unaudited financial results for the first quarter of 2015.
Net revenue for the first quarter of 2015 was US$1,054.3 million, representing a decrease of about 22% from US$1,357.3 million for the comparable period in 2014. The decline in net revenue was primarily attributable to lower group-wide rolling chip revenues and mass market table games revenues.
On a U.S. GAAP basis, net income attributable to Melco Crown Entertainment for the first quarter of 2015 was US$60.6 million, or US$0.11 per ADS, contrast with net income attributable to Melco Crown Entertainment of US$239.5 million, or US$0.44 per ADS, in the first quarter of 2014. The net loss attributable to non-controlling interests during the first quarter of 2015 of US$36.8 million related to Studio City and City of Dreams Manila.
Melco Crown Entertainment Limited, through its auxiliaries, develops, owns, and operates casino gaming and entertainment resort facilities in Asia. It owns and operates City of Dreams, an integrated casino resort that has 500 gaming tables and 1,400 gaming machines; about 1,400 hotel rooms and suites; a wet stage performance theater with about 2,000 seats; about 30 restaurants and bars, and 70 retail outlets.
At the end of Thursday’s trade, Shares of The Boeing Company (NYSE:BA), gained 0.32% to $141.49.
The Boeing Company, and CFM International declared that they successfully initiated flight testing of the LEAP-1B engine on April 29 on a modified 747 flying testbed at GE Aviation Flight Test Operations in Victorville, Calif.
The testing is the next major milestone in a two-year program that will culminate in engine certification in 2016 and delivery of the first Boeing 737 MAX in 2017. The engine performed well and accomplished multiple aeromechanical test points at various altitudes during the five hour, 30 minute first flight.
The LEAP-1B engine is the exclusive powerplant for the Boeing 737 MAX family and is part of the most extensive ground and flight test certification program in CFM’s history. The first LEAP-1B engine began ground testing on June 13, 2014, three days ahead of the plan set when the program was launched in 2011.
The Boeing Company, together with its auxiliaries, designs, develops, manufactures, sells, services, and supports commercial jetliners, military aircraft, satellites, missile defense, human space flight, and launch systems and services worldwide.
Finally, Exelixis, Inc. (NASDAQ:EXEL), ended its last trade with 5.42% gain, and closed at $3.11.
Exelixis, declared that Michael M. Morrissey, Ph.D., the company’s president and chief executive officer, will provide an overview of the company at the Bank of America Merrill Lynch 2015 Health Care Conference taking place May 12-14 in Las Vegas, NV. The Exelixis presentation is planned for 12:00 p.m. PDT/3:00 p.m. EDT on Tuesday, May 12, 2015.
Exelixis, Inc., a biopharmaceutical company, develops and sells small molecule therapies for the treatment of cancer in the United States. The company offers COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of patients with progressive, metastatic medullary thyroid cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
